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Abstract
Immune responses to enzyme replacement therapy (ERT) have been reported and can result in a hypersensitivity/
anaphylactic reaction during or immediately after enzyme infusion. We have investigated the infusion of the lysosomal
enzyme N-acetylgalactosamine 4-sulphatase (4-sulphatase) into immunized, high titre rats as a model of immune response to
ERT. To simulate ERT, high and low titre rats were infused with different doses of radiolabelled recombinant human 4-
sulphatase (3H-rh4S). There was evidence of altered targeting, inactivation and degradation of 4-sulphatase in high titre (titre
1 024 000) compared to low titre (titre 64) rats. There was more 4-sulphatase enzyme activity detected in 5 mg/kg high titre
rats when compared to 1 mg/kg high titre rats, suggesting that the antibodies could be saturable in vivo. However, the rats
treated with 5 mg/kg 3H-rh4S all had clinical signs of hypersensitivity reactions to 4-sulphatase infusion. There were no
apparent signs of adverse reactions in either the high titre 1 mg/kg rats or the low titre rats (1, 5 mg/kg). The high titre 5 mg/
kg rats also had changes in 3H-rh4S distribution, with lower levels delivered to the liver and a marked increase in the level
remaining in plasma, when compared to either 1 mg/kg high titre rats or low titre rats (1, 5 mg/kg). ß 1998 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Several treatment strategies have been proposed
for inborn errors of metabolism patients and they
include displacement bone marrow transplantation
[1], enzyme replacement therapy [2^5] and somatic
cell gene replacement therapy [6^8]. All of these pro-
posed therapies rely on providing an alternative
functional source of the patients’ missing or defective
protein. Despite some successes there are some inher-
ent problems with bone marrow transplantation,
which may include ¢nding a suitable donor, graft
versus host disease, graft rejection and the safety of
the protocol. With gene replacement therapy still in
the developmental phase, enzyme replacement ther-
apy may be the best option for the treatment of in-
born errors of metabolism patients, at least in the
near future.
Recently, the e⁄cacy of enzyme replacement ther-
apy (ERT) has been evaluated as a treatment strat-
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egy for lysosomal storage disorder patients, using
animal models. ERT in a mouse model of Sly syn-
drome (mucopolysaccharidosis type VII or MPS VII)
has demonstrated successful correction of L-glucuro-
nidase enzyme activity in most tissues [5,9]. These
MPS VII ERT treated mice had less clinical and
pathological evidence of disease when compared to
untreated MPS VII mice. Treatment from birth was
identi¢ed as an important strategy [9]. Another study
has reported the evaluation of ERT in a canine mod-
el of Hurler syndrome (MPS I) and demonstrated
clearance of storage product in liver, spleen and kid-
ney but not brain heart and cornea [10]. MPS VI cats
(cat equivalent of human Maroteaux-Lamy syn-
drome) have also been treated with ERT using re-
combinant human 4-sulphatase (rh4S), as a prelude
to clinical trials in human MPS VI patients [11,12].
MPS VI cats treated with rh4S ERT demonstrated a
dose dependent reduction of lysosomal storage in the
liver, skin ¢broblasts, aorta, heart valve and in brain
perivascular cells, and reduced skeletal pathology,
when compared to untreated MPS VI cats.
Clinical trials of ERT in human patients with
Gaucher disease have been established and yielded
promising results [4,13,14]. Gaucher patients on
long term ERT demonstrated improved visceral, hae-
matological and skeletal parameters, with reduced
levels of glucocerebroside storage product in macro-
phages [4,15^17].
Studies of the e⁄cacy of replacement therapies in
animal models and human Gaucher patients have
established that ERT is an e¡ective treatment strat-
egy for lysosomal storage disorders. However, poten-
tial problems with ERT have been recognised. In the
animal model studies and in Gaucher patients, anti-
bodies to the replacement protein have been reported
[9^11,14,18]. Our studies in the MPS VI cat, and a
model system using 4-sulphatase immunized rats,
suggested that antibody can have a signi¢cant e¡ect
on enzyme targeting and half-life [11,18].
Some Gaucher patients produced antibodies to
the L-glucocerebrosidase replacement protein within
1 year of commencing ERT (approx. 10^20% of pa-
tients; see for example [19]) and some antibody pos-
itive patients showed signs of hypersensitivity reac-
tions to enzyme infusion. The patients with signs of
adverse reactivity were treated with immunoprophy-
lactic measures and most were able to continue ther-
apy. Recently, two Gaucher patients receiving ERT
were shown to develop circulating antibodies to L-
glucocerebrosidase during the course of treatment
and this was associated with plateaued improve-
ment/disease progression [20]. Notably, the antibod-
ies produced to acid L-glucosidase inactivated the
normal wild type protein but not the patients’
N370S mutant form of the protein [20]. This re£ects
the ability of the immune system to speci¢cally detect
structural di¡erences between normal and mutant
protein.
The potential development of immune-mediated
complications during ERT treatment of patients is
an important consideration for the e⁄cacy of the
therapy and the well being of the patient. Two major
problems have been identi¢ed in association with
antibody responses to ERT: hypersensitivity/anaphy-
lactic reactions either during or immediately after
enzyme infusion and reduced e⁄cacy of ERT due
to antibody induced inactivation and/or degradation
of enzyme. It is postulated that a number of enzyme
treated patients will develop circulating antibodies to
replacement protein and that antibody reactivity may
in some cases prove to be detrimental to the e⁄cacy
of the treatment. Here we investigate a model system
using high and low titre rats to evaluate the e¡ects of
antibody on ERT and the onset of clinical signs of
hypersensitivity in high titre rats after enzyme infu-
sion.
2. Materials and methods
2.1. Materials
Polyvinylchloride plates (96 well) and 75 cm2 cul-
ture £asks were obtained from Costar (Cambridge,
MA, USA). Rabbit anti-rat immunoglobulin and
peroxidase labelled rabbit anti-rat immunoglobulin
reagents were purchased from Sigma Immunochem-
icals, Sigma-Aldrich (Castle Hill, NSW, Australia).
ABTS substrate kits and A⁄-Gel 10 were from
Bio-Rad (Richmond, VA, USA) and used according
to the manufacturer’s instructions. 4-Methylumbelli-
feryl sulphate (MUS) was obtained from Koch-Light
(Haverhill, Su¡olk, UK). Phosphate bu¡ered saline
(PBS) without magnesium or calcium was from CSL
(Parkville, Victoria, Australia).
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2.2. Immunoassay of anti-rh4s antibodies
An ELISA assay was used to determine the titre of
anti-rh4S antibodies from rat plasma. A 50 Wl aliquot
of rh4S (10 Wg/ml in PBS pH 7.2) was added to each
well of a polyvinyl chloride plate and incubated for
2 h at 37‡C followed by overnight incubation at 4‡C.
The unbound 4-sulphatase was aspirated from each
well and then any remaining reactive sites on the
plate blocked by three washes of 200 Wl of 0.02 M
Tris-HCl, pH 7.0 containing 0.25 M NaCl and 1%
(w/v) ovalbumin. After the third wash the wells were
incubated in 200 Wl of the same bu¡er for at least 2 h
at 20‡C. Test samples and control plasma were pre-
absorbed with ovalbumin/BSA coupled A⁄-Gel 10
(10 mg of each protein was coupled to 1 ml of
A⁄-Gel 10, using the manufacturer’s instructions),
then serially diluted in 0.02 M Tris-HCl, pH 7.0,
containing 0.25 M NaCl and 1% (w/v) ovalbumin
and incubated on the rh4S coated wells (4 h at
20‡C). Each well was then aspirated and washed
three times with 200 Wl of 0.02 M Tris-HCl, pH
7.0, containing 0.25 M NaCl and 1% (w/v) ovalbu-
min. Wells were then aspirated and incubated with
100 Wl of a peroxidase-labelled rabbit anti-rat Ig (1/
2000 dilution (v/v) in 0.02 M Tris-HCl, pH 7.0, con-
taining 0.25 M NaCl and 1% (w/v) ovalbumin) for 1 h
at 20‡C. The unbound antibody was aspirated and
the wells washed three times in 200 Wl 0.02 M Tris-
HCl, pH 7.0, containing 0.25 M NaCl, before adding
100 Wl per well of a peroxidase substrate solution
(ABTS substrate kit). After 20 min incubation at
20‡C, colour development was quanti¢ed by measur-
ing absorbency at 414 nm on an automated ELISA
reader (Ceres 900 Hdi, Bio-Tek Instruments, Wi-
nooski, VT, USA). All anti-rh4S reactivities were
compared to a negative control which determined
the reactivity of the plasma with ovalbumin.
2.3. Recombinant human 4-sulphatase (rh4S) and
radiolabelled rh4S (3H-rh4S) for enzyme infusion
rh4S and 3H-rh4S were prepared and puri¢ed as
previously described [18]. Injection of 4-sulphatase
(in PBS at 1^3 mg/ml) was by intravenous infusion,
usually at a rate of 5^10 ml/kg/h, but no more than
90 ml/kg/h. The speci¢c activity of the 3H-rh4S after
puri¢cation was 40^80 dpm/nmol and rats received
doses containing 1.25^1.8U106 dpm (i.e. adjusted to
¢nal dose with puri¢ed unlabelled rh4S). Due to in-
accuracies with i.v. injection and the spiking of sam-
ples with 3H-rh4S the doses injected into the 1 mg/kg
treatment group varied from 1.2 to 1.6 mg/kg and in
the 5 mg/kg treatment group varied from 4.5 to 5.2
mg/kg (the doses for each rat have been listed in the
¢gure and table legends). For the purposes of general
discussion these doses have been referred to as either
1 or 5 mg/kg.
2.4. In vivo enzyme distribution studies in rats
To determine the e¡ect of anti-rh4S antibody on
enzyme distribution in vivo, normal control rats were
selected either on the basis of low titres to rh4S (titre
64) or were immunized with rh4S to induce antibody
responses (titre 1 024 000) and then infused with 3H-
rh4S. Anti-rh4S antibodies were induced in normal
control rats by the injection of 50 Wg doses of puri-
¢ed rh4S in Freund’s adjuvant. One injection of
Freund’s complete adjuvant (0.15 ml adjuvant with
0.15 ml of rh4S in PBS) was given subcutaneously as
a priming dose and followed by three subcutaneous
injections of rh4S in Freund’s incomplete adjuvant at
three weekly intervals. Plasma samples for antibody
titre determination were obtained by tail vein bleed-
ing of anaesthetized rats. Antibody titres in rats were
con¢rmed by ELISA of plasma antibodies, then the
rats were injected intravenously with either 1 or 5
mg/kg of 3H-rh4S (containing 1.25^1.8U106 dpm
3H-rh4S). Rats were sacri¢ced at 60 min after injec-
tion and analysed for the distribution of 3H-rh4S in
di¡erent tissues.
2.5. Detection of 4-sulphatase activity and 3H-rh4S
in rat tissue extracts
Preparation of tissue samples, granular fractiona-
tion of rat liver and Percoll gradient separation of
organelles was as previously described [18]. An en-
zyme immunobinding assay was used to speci¢cally
detect 4-sulphatase activity [18]. To determine the
level of 3H-rh4S in di¡erent tissues, samples were
dissected into small fragments and solubilized over-
night at 22‡C in 1 M NaOH (5 ml/g of tissue). 200 Wl
of sample was neutralized with HCl then mixed with
500 Wl of NCS tissue solubilizer/isopropanol (1:2 v/
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v). After 15 min at 22‡C, 100 Wl of 30% H2O2 was
added, mixed and allowed to incubate for a further
60 min at 22‡C. Optiphase ‘Hi Safe 3’ liquid scintil-
lant (15 ml) was then added and the samples counted
Fig. 1. Distribution of radiolabelled 4-sulphatase in Percoll fractions of liver from high and low titre rats. The Percoll granular frac-
tionations are from two low titre rats (1.6, 5.2 mg/kg 3H-rh4S) and two high titre rats (1.6, 5.2 mg/kg 3H-rh4S). Results represent ra-
diolabelled 4-sulphatase in dpm/500 Wl of each fraction (total fraction volume was 1 ml). Each of the four rats had an equal amount
of radiolabel (3H-rh4S) infused, which was made up to the equivalent of either the 1.6 or 5.2 mg/kg dose with cold rh4S. In all of the
Percoll gradients L-hexosaminidase was detected in fractions 24^26, characteristic of lysosomal organelles.
Table 1
Distribution of radiolabelled 4-sulphatase infused at two di¡erent doses in high and low titre rats
Tissue Low titre (1 mg/kg; n = 4) Low titre (5 mg/kg; n = 2) High titre (1 mg/kg; n = 4) High titre (5 mg/kg; n = 3)
Liver 59 021 þ 2 217 39 332* 51 561 þ 8 136 19 600 þ 9 831
Lung 2 893 þ 588 3 483* 27 664 þ 13 738 14 793 þ 6 804
Spleen 26 413 þ 5 233 20 157* 20 368 þ 3 481 10 862 þ 1 856
Kidney 1 947 þ 878 9 425* 2 460 þ 1 768 3 141 þ 1 430
Heart 1 932 þ 268 2 501* 2 652 þ 1 407 2 124 þ 744
Plasma 1 025 þ 230 4 260* 430 þ 160 37 812 þ 15 879
Results are the means þ S.D. of the levels of radiolabelled 4-sulphatase in tissues (dpm/g) or plasma (dpm/ml), except for those marked
* which represent the mean of duplicate results. Rats were sacri¢ced 60 min after the infusion of 3H-rh4S (adjusted to approx.
1.2U106 dpm of 3H-rh4S per dose). The doses of 3H-rh4S administered to each of the rats were: low titre (n = 4) 1.2, 1.2, 1.2, 1.6
mg/kg; low titre (n = 2) 5.1, 5.2 mg/kg; high titre (n = 4) 1.2, 1.2, 1.2, 1.4 mg/kg; high titre (n = 3) 4.5, 5.2, 5.2 mg/kg. n, number of
rats investigated. Tissue weights in g for the 13 animals used in this study were: liver, 10.01 þ 0.8; lung, 1.52 þ 0.2; spleen, 0.54 þ 0.2;
kidney, 2.15 þ 0.2; heart, 1.24 þ 0.3.
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on a Wallac liquid scintillation counter. Results were
expressed as dpm/g of tissue wet weight and used to
calculate the total level of radioactivity (3H-rh4S) in
tissues.
Fig. 2. Distribution of 4-sulphatase activity in Percoll fractions of liver from high and low titre rats. The Percoll granular fractiona-
tions are from two low titre rats (1.6, 5.2 mg/kg 3H-rh4S) and two high titre rats (1.6, 5.2 mg/kg 3H-rh4S). 4-Sulphatase enzyme activ-
ities are expressed as nmol/min. In all of the Percoll gradients L-hexosaminidase was detected in fractions 24^26, characteristic of lyso-
somal organelles. The recovery of enzyme activities in Percoll fractions compared to whole livers were between 3 and 5% based on
the recovery of L-hexosaminidase activity. The total levels of 4-sulphatase activity in unfractionated livers were calculated to be 6213
nmol/min (low titre rat, 1.6 mg/kg); 17 121 nmol/min (low titre rat, 5.2 mg/kg); 453 nmol/min (high titre rat, 1.6 mg/kg); and 6966
nmol/min (high titre rat, 5.2 mg/kg).
Table 2
Distribution of 4-sulphatase enzyme activity infused at two di¡erent doses in high and low titre rats
Tissue Low titre (1 mg/kg; n = 4) Low titre (5 mg/kg; n = 2) High titre (1 mg/kg; n = 4) High titre (5 mg/kg; n = 3)
Liver 368 þ 131 2046* 23.3 þ 13 1193 þ 387
Lung 8.5 þ 5.5 66* 10 þ 4 381 þ 300
Spleen 134 þ 96 646* 7 þ 6 439 þ 216
Kidney 12 þ 7 151* 0.7 þ 0.3 143 þ 76
Heart 3.1 þ 1.7 52* 0.5 þ 0.3 97 þ 59
Plasma 0.6* 210* 0.04* 2155 þ 1263
Results are the means þ S.D. of 4-sulphatase enzyme activity (nmol/min/g for tissues and nmol/min/ml for plasma samples), except for
those marked * which represent the mean of duplicate results. Rats were sacri¢ced 60 min after 4-sulphatase 3H-rh4S infusion. n,
number of rats investigated. The doses of 3H-rh4S administered and tissue weights for the rats were as listed in the legend of Table 1.
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2.6. Immunoblot detection of 4-sulphatase in high and
low titre rats
Fractions from Percoll gradients were pooled (1^6,
7^10, 11^14, 15^18, 19^22 and 23^27), adjusted to
0.5 M NaCl and freeze thawed six times. Organelle
membranes were removed by centrifugation
(100 000Ug for 1 h at 4‡C). The proteins in the
supernatants were then precipitated for SDS-
PAGE, by adding 50 Wl of sodium deoxycholate to
each sample for 90 min at 4‡C, then 0.5 ml of 12%
trichloroacetic acid for 60 min at 4‡C and the pre-
cipitate recovered by centrifugation at 2000Ug for 10
min at 4‡C. The precipitates were each washed three
times with 10 ml of ice-cold acetone and once with
ice-cold ether (precipitates recovered by centrifuga-
tion at 2000Ug for 10 min at 4‡C). The ether was
removed and the pellets allowed to dry at 20‡C. Sam-
ples were solubilized in reducing sample bu¡er for
SDS-PAGE and immunoblotted using an a⁄nity pu-
ri¢ed polyclonal anti-4-sulphatase antibody using a
previously described method [21]. Immunoblots were
visualized by enhanced chemiluminescence (ECL) de-
tection using the manufacturer’s instructions (NEN
research products: Dupont, Melbourne, Victoria,
Australia).
3. Results
3.1. Distribution of 3H-rh4S in high and low titre rats
Low titre rats (titre 64) and high titre rats (titre
1 024 000) were infused intravenously with doses of
either 1 or 5 mg/kg 3H-rh4S to simulate ERT, then
sacri¢ced 60 min later for distribution studies. In low
titre rats the 3H-rh4S was distributed mainly in liver
as detected by both radiolabel (Table 1) and 4-sul-
phatase activity (Table 2). The low titre rats infused
with 5 mg/kg 3H-rh4S had lower levels of radiolabel
in the liver when compared to the low titre rats in-
fused with 1 mg/kg 3H-rh4S, suggesting a minor
change in enzyme distribution (Table 1). Approx.
5 times the level of 4-sulphatase activity was, however,
detected in the liver of the 5 mg/kg 3H-rh4S low titre
rats when compared to the 1 mg/kg 3H-rh4S low titre
rats and similar increases were observed in other tis-
sues (Table 2). There was also an increase in the level
of radiolabelled 4-sulphatase detected in the plasma
from 5 mg/kg 3H-rh4S low titre rats when compared
to the 1 mg/kg 3H-rh4S low titre rats (Table 1) and
this was enzymically active 4-sulphatase (Table 2).
The high titre rats infused with 1 mg/kg 3H-rh4S
had a similar distribution of radiolabel when com-
pared to the low titre rats infused with 1 mg/kg 3H-
rh4S, but with an increase in the level of radiolabel
detected in the lung (Table 1). There was, however, a
marked reduction of 4-sulphatase enzyme activity
(Table 2) in all of the tissues of the high titre com-
pared to the low titre rats (infused with 1 mg/kg 3H-
rh4S), with the exception of lung which showed sim-
ilar activity levels (but associated with an increase in
radiolabel).
The high titre rats infused with 5 mg/kg 3H-rh4S
had a marked change in the distribution of radio-
label when compared to the 1 mg/kg 3H-rh4S high
titre rats and the low titre rats (1, 5 mg/kg 3H-rh4S),
with lower levels of radioactivity detected in the liver
Fig. 3. Immunoblot detection of 4-sulphatase protein in Percoll
fractions of liver from high and low titre rats. For each rat,
Percoll fractions were pooled 1^6, 7^10, 11^14, 15^18, 19^22
and 23^27 and electrophoresed in six separate lanes on SDS-
PAGE. The Percoll granular fractionations are from a low titre
rat (lanes 1^6) and a high titre rat (lanes 6^12), both treated
with 5.2 mg/kg 3H-rh4S. 4-Sulphatase blots were reacted with
an a⁄nity puri¢ed polyclonal antibody to human 4-sulphatase
and a peroxidase labelled sheep anti-rabbit second antibody,
then visualized using ECL detection as described in Section 2.
N.B.: The anti-human 4-sulphatase polyclonal antibody, used
to detect the 3H-rh4S, had cross-reactivity with rat 4-sulphatase
(in an immunobinding assay [18], data not presented). However,
in control granular fractions (i.e. rats not infused with 3H-rh4S)
there was no detectable immunoblot reactivity with the anti-hu-
man 4-sulphatase polyclonal antibody (data not shown), re£ect-
ing the low level of 4-sulphatase normally present in rat granu-
lar fractions.
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and spleen, and high levels of radiolabel detected in
the plasma (Table 1). Like the 1 mg/kg 3H-rh4S high
titre rats, the 5 mg/kg 3H-rh4S high titre rats had
high levels of radiolabel in the lung when compared
to either 1 or 5 mg/kg low titre rats (Table 1). How-
ever, unlike the high titre rats infused with 1 mg/kg
3H-rh4S, the high titre rats infused with 5 mg/kg 3H-
rh4S had tissue levels of 4-sulphatase enzyme activity
(Table 2), which were comparable to the levels de-
tected in the low titre rats infused with 5 mg/kg 3H-
rh4S (excluding the reduced level of radiolabel and
activity reaching the liver of the 5 mg/kg 3H-rh4S
high titre rats: Table 1). The 3H-rh4S detected as
radiolabel in the plasma from the high titre rats in-
fused with 5 mg/kg 3H-rh4S also had 4-sulphatase
enzyme activity (Table 2).
3.2. Subcellular distribution of 4-sulphatase in low and
high titre rats treated with two di¡erent doses of
3H-rh4S
Four rats were infused with equal amounts of ra-
diolabel; a 1 mg/kg 3H-rh4S low titre rat, a 1 mg/kg
3H-rh4S high titre rat, a 5 mg/kg 3H-rh4S low titre
rat and a 5 mg/kg 3H-rh4S high titre rat (N.B.: un-
labelled rh4S was used to make up the level of 4-
sulphatase to the appropriate dose). Sixty minutes
after enzyme infusion, the rats were sacri¢ced and
liver granular fractions prepared and separated on
Percoll gradients, to determine the subcellular distri-
bution of 4-sulphatase radiolabel and enzyme activ-
ity. The low titre rat infused with 1 mg/kg 3H-rh4S
had radiolabel (Fig. 1) and 4-sulphatase enzyme ac-
tivity (Fig. 2) detected mainly in fractions 24^26,
which was coincident with L-hexosaminidase activity
and characteristic of lysosomes. The low titre rat
infused with 5 mg/kg 3H-rh4S had a similar distribu-
tion of radiolabel to the low titre rat infused with
1 mg/kg 3H-rh4S (Fig. 1), but with a slightly reduced
level of radioactivity in fractions 24^26 and a small
increase in the level in fractions 8^15. A similar dis-
tribution to the latter was observed for 4-sulphatase
enzyme activity (Fig. 2), but with a relative increase
in activity in fractions 24^26 re£ecting the increased
dose of enzyme (i.e. 5 compared to 1 mg/kg 3H-
rh4S).
The high titre rat infused with 1 mg/kg 3H-rh4S
had an altered distribution of radiolabel when com-
pared to the low titre rats, with reduced levels of
radiolabel in fractions 24^26 and a spread of radio-
label in fractions 14^24 (Fig. 1). There was, however,
an overall reduction in the level of radiolabel recov-
ered across the gradient. In the high titre rat infused
with 1 mg/kg 3H-rh4S there was only minimal
amounts of 4-sulphatase enzyme activity detected in
the Percoll fractions (Fig. 2).
The high titre rat infused with 5 mg/kg 3H-rh4S
also had an altered distribution of radiolabel when
compared to the low titre rats with a reduced level of
radiolabel in fractions 24^27 and an additional peak
of radiolabel in fractions 8^16. Unlike the high titre
rat infused with 1 mg/kg 3H-rh4S, the high titre rat
infused with 5 mg/kg 3H-rh4S had 4-sulphatase en-
zyme activity associated with the latter two peaks.
This activity was less than that detected in the low
titre rat infused with 5 mg/kg 3H-rh4S (i.e. same
dose).
3.3. Fate of 4-sulphatase in high and low titre rats
treated with 5 mg/kg 3H-rh4S
To investigate the processing/degradation of 3H-
rh4S protein, the Percoll fractions from the two
rats treated with 5 mg/kg 3H-rh4S (one high titre,
one low titre) were each pooled into seven fractions,
run on SDS-PAGE and immunoblotted using an af-
¢nity puri¢ed polyclonal antibody against 4-sulpha-
tase. In the fractions from the high titre rat the 4-
sulphatase was detected mainly as a 66 kDa precur-
sor polypeptide and appeared to be spread across the
gradient with reduced levels of 4-sulphatase protein
present in the fractions characteristic of lysosomes
(Fig. 3, lane 6). Much more 4-sulphatase was de-
tected in the Percoll fractions from the low titre
rat, with evidence of protein processing. The 4-sul-
phatase protein bands were more di¡use and the 43
kDa mature form of 4-sulphatase was detected,
mostly in the fractions characteristic of lysosomes
(Fig. 3, lane 12). Little or no mature 4-sulphatase
was detected in the fractions from the high titre rat.
3.4. Development of hypersensitivity reactions in high
titre 5 mg/kg 3H-rh4S treated rats
No signs of adverse immune reactivity were de-
tected in either the low titre rats (1, 5 mg/kg 3H-
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rh4S) or the high titre rats infused with 1 mg/kg 3H-
rh4S. However, the high titre rats infused with 5 mg/
kg 3H-rh4S all had clinical signs of hypersensitivity
reactions shortly after enzyme infusion. These rats
were lethargic and slow to recover from anaestheti-
zation post enzyme infusion, and all had respiratory
distress which required oxygen treatment.
5. Discussion
Animal model studies and recent clinical trials
with Gaucher patients have demonstrated that ERT
can be e¡ective in the treatment of patients with
lysosomal storage disorders [4,5,9^13,17]. Replace-
ment therapies have also been developed for other
disorders including, factor VIII treatment of haemo-
philia [22^24] and insulin treatment of diabetes
[25,26]. In all of these replacement therapies, cases
of immunological responses to the replacement pro-
tein have been reported.
In Gaucher disease between 10 and 20% of pa-
tients receiving ERT have produced antibodies to
the L-glucocerebrosidase replacement protein
[14,19,20]. The incidence of IgG antibody production
has been reported to be higher in Ceredase (40%:
natural puri¢ed protein) compared to Cerezyme
(20%: recombinant protein) treated Gaucher patients
[27]. Moreover, some antibody responsive Gaucher
patients have developed signs of hypersensitivity/ana-
phylactic reactions during enzyme infusion and re-
quired immunoprophylactic treatment. In haemo-
philia, antibodies to factor VIII have been reported
in 5^30% of patients receiving replacement therapy
[22^24]. In some patients with insulin dependent
(type I) diabetes mellitus, antibodies to insulin are
present at diagnosis, but after the initiation of insulin
replacement therapy almost all patients have autoan-
tibodies which are IgG subclass antibodies [25,26]. In
animal model studies for lysosomal storage disorders
antibody responses to ERT have been reported [9^
11,18]. In the canine model of MPS I most dogs
produced antibodies to the K-L-iduronidase replace-
ment protein, while in the feline model of MPS VI
24% of cats reacted to ERT with higher than normal
levels of antibody to 4-sulphatase. In MPS VII mice
treated by ERT, antibodies to L-glucuronidase have
been reported and 50% of mice had mild to severe
anaphylactic reactions in response to enzyme infu-
sion. However, in the latter study, some of this ad-
verse reactivity was attributed to the serum albumin
used to stabilize the enzyme preparation [9].
It is concluded that some but not necessarily all
patients will develop an immune response to replace-
ment therapy. The response to ERT may be depend-
ent upon a variety of factors including the properties
of the replacement protein (e.g. size, structural ri-
gidity, glycosylation), the dose and route of admin-
istration, the frequency of treatment, the genetic
background of the patient, the presence of residual
mutant protein in the patient and/or the structural
di¡erence between the normal and mutant protein.
However, in patients that do develop an immune
response to ERT, several distinct problems may be
encountered. Circulating antibodies to the replace-
ment protein can potentially result in enzyme inacti-
vation (neutralization [11,20]), enzyme degradation
[18], altered enzyme targeting [18] and hypersensitiv-
ity reactions to the infused enzyme.
This study has used 3H-rh4S (i.e. radiolabelled re-
combinant human 4-sulphatase) for infusion into
high titre rats and has assumed that any species dif-
ferences between human and rat 4-sulphatase would
only serve to enhance the antibody reactivity pro-
duced during the immunization process. Moreover,
these sequence and structural di¡erences may ap-
proximate the di¡erences between the normal ERT
infusion protein and the mutant protein present in
MPS patients. Importantly, an immune response to
ERT in a Gaucher patient has been reported to re-
sult in antibodies which selectively inactivated nor-
mal acid L-glucosidase but not the patient’s mutant
acid L-glucosidase [20], re£ecting the recognition of a
structural di¡erence between the normal and mutant
protein. We have used immunized rats as a model
system to study the e¡ects of high titre antibodies
on 4-sulphatase ERT, representing the worse case
scenario for an immune response during the treat-
ment of MPS VI patients.
In normal control low titre rats, a major propor-
tion of 3H-rh4S (1 mg/kg) was distributed to the liver
60 min after infusion and appeared to be rapidly
localized into the lysosomal compartment. In low
titre rats, increasing the dose from 1 to 5 mg/kg
3H-rh4S only resulted in minor changes in enzyme
distribution, with slightly slower clearance from plas-
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ma and in Percoll gradients, there was evidence of
slower transition of 3H-rh4S to the lysosomal com-
partment where processing to the mature form oc-
curred. In general, the 5 times higher dose resulted in
a 5-fold increase in 3H-rh4S in all tissues examined.
This is consistent with previous studies in MPS VI
cats demonstrating a dose dependent correction of
pathophysiology [12] and similar studies in the
MPS I dog showing increased tissue activity and en-
hanced correction of glycosaminoglycan storage at
higher doses [28].
In high titre rats infused with 1 mg/kg 3H-rh4S
there was an increase in radiolabel detected in lung,
compared to low titre rats. In Percoll fractions of
liver lower levels of radiolabel were detected in the
granular fraction, when compared to the low titre
rats, despite similar total levels of radiolabel in the
liver. This suggested that either the 3H-rh4S had
been degraded for reutilization within the liver or
was prevented from entering the vacuolar network.
The former was more likely based on our previous
observations, which showed rapid loss of radiolabel
(3H-rh4S) from granular fractions of liver in high
titre rats [18]. Moreover, the 3H-rh4S in the Percoll
fractions of liver from the 1 mg/kg high titre rats had
only minimal 4-sulphatase enzyme activity, consis-
tent with enzyme inactivation/degradation. Together
these results indicated that high titre antibodies could
have a dramatic e¡ect on the e⁄cacy of ERT.
We have previously shown that in MPS VI cats,
rh4S infusion (1 mg/kg) could temporarily remove
circulating antibodies to 4-sulphatase, potentially
generating a window of opportunity in which to de-
liver an e¡ective dose of enzyme [18]. It was pro-
posed that by increasing the dose of rh4S infused,
from 1 to 5 mg/kg, the same e¡ect may be generated
in a single treatment. However, high titre rats treated
with 5 mg/kg 3H-rh4S all had hypersensitivity reac-
tions, whereas 1 mg/kg high titre rats and low titre
rats (1, 5 mg/kg) had no signs of this adverse reac-
tivity. The hyperreactivity appeared to be associated
with altered tissue distribution and subcellular target-
ing. High levels of 4-sulphatase enzyme activity were
detected in plasma from high titre rats (5 mg/kg) and
lower levels of 4-sulphatase reached the liver, when
compared to 1 mg/kg high titre rats. This plasma
localization is presumably due to the formation of
an extensive antibody-antigen complex within the cir-
culatory system. Unlike the 1 mg/kg high titre rats,
the 3H-rh4S reaching the liver in the 5 mg/kg high
titre rats was enzymically active, indicating that the
antibodies causing the redistribution were not neu-
tralizing antibodies. There was also evidence of ac-
tive 4-sulphatase in lower density organelles charac-
teristic of endosomes, suggesting a delay in transfer
of this 4-sulphatase to the lysosomal compartment.
This active 4-sulphatase detected in liver may repre-
sent enzyme that has avoided interaction with anti-
body. There was, however, no processing of the
4-sulphatase to the mature form in the 5 mg/kg
high titre rat implying incorrect subcellular targeting
and reduced levels of protein in the fractions char-
acteristic of lysosomes. This could again be consis-
tent with rapid degradation in a lysosomal compart-
ment.
High titre antibody responses to ERT will poten-
tially cause problems with enzyme inactivation/deg-
radation, altered targeting, altered subcellular distri-
bution, and enzyme processing, and may also lead to
the onset of symptoms associated with either hyper-
sensitivity reactions or anaphylaxis. For these rea-
sons patients with detectable antibody titres to a re-
placement protein should be carefully monitored
during enzyme infusion and assessed for the e⁄cacy
of treatment. The induction of immunological toler-
ance [20], or the removal of reactive antibodies prior
to the administering of an e¡ective treatment dose
[23], may prove to be e¡ective strategies for treating
immune responsive patients.
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